French Govt Must Act To Stop ‘Inexorable Decline’ Of Pharmaceutical Industry
Executive Summary
The president of France’s industry association Leem says the authorities need to look at new ways of handling the health technology evaluation and pricing of innovative drugs, and to implement more predictable, long-term health policies, if the country is to reverse the “inexorable decline” of the pharmaceutical sector.
You may also be interested in...
New French Pharma Industry Head Faces Tough Challenges On Drug Spending
Leem’s new president says one of his priorities is to discuss the implementation of measures agreed earlier this year to speed up access to innovative medicines. But he also faces a number of other challenges, including the squeeze on pharmaceutical spending.
French Govt Plans To Boost Access To Innovation & Increase Use Of Generics & Biosimilars
The French government’s health strategy for 2018-2022 includes a range of measures to increase patient access to new medicines, raise the level of generic and biosimilar prescribing, and cut down on the use of antibiotics.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.